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1. Introduction 
Colitis is a very complex disease entity with several etiologic and pathogenesis charactistics. 
It may have acute or chronic forms that may be with significant morbidity and negative 
effect on the quality of life of the patient. While the most common and recognizable forms 
are those of infectious etiologies, however, other forms include ulcerative, Crohn’s, 
immunologic, vascular, pseudo membranous, lymphocytic and collagenous types, to name 
some. Many different classes of pharmaceutical agents, including non-steroidal anti-
inflammatory agents, cyclooxygenase-2 inhibitors, statins, triptans, anti-viral agents, 
hormone replacement therapies, antidepressants, and antibiotics, are known to induce 
colitis.1-4 Colitis is also a well documented side effect of chemotherapy. Chemotherapy-
induced colitis may manifest in different clinical settings and have serious sequelae that 
may impact patient care and outcomes.  
Over the past few decades, several novel cytotoxic agents have been found to cause 
significant gastrointestinal toxicity. The presentation and pathological characteristics of  
the colitis induced by these novel agents do not necessarily adhere to the traditional 
description of neutropenic enterocolitis. These newer forms of colitis include taxane-induced 
colits5-10 and anti–cytotoxic T-lymphocyte antigen-4 antibody immune-breakthrough 
enterocolitis.11-14  
Description of colitis induced by other commonly used cytotoxic agents include reports of 
cases caused by vinorelbine,15 capecitabine,16 interferon,17 bevacizumab,18,19 rituximab,20 
dasatinib,21 and topotecan.22-24 Given the increasingly frequent use of chemotherapeutic 
agents capable of causing colitis, clinicians and oncologists should be knowledgeable of this 
complex condition and its various pathogeneses, risk factors, and prognoses to enhance 
patient care.  
In this chapter we will review the clinical characteristics of the well-known and traditional 
neutropenic colitis; in addition, we will discuss the more recently described colitis induced 
by taxanes and by anti-CTLA-4 antibody.   
2. Neutropenic enterocolitis 
Netropenic colitis is a well recognized entity, however, encountered among cancer patients 
undergoing chemotherapy treatment. It was the first form of chemotherapy-induced colitis 
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to be described in literature and is a well-known clinical syndrome. Mortality among 
patients with neutropenic enterocolitis, mainly due to sepsis and bowel perforation, has 
been reported at rates exceeding 50%.25, 26 Early recognition of this condition may lead to 
lower mortality rates, but no prospective studies have explored this topic.  
Neutropenic enterocolitis has been known by several names, including typhlitis (from the 
Greek typhlon),27 neutropenic colitis, necrotizing enterocolitis, ileocecal syndrome, and 
cecitis.25, 28 In 1962, neutropenic enterocolitis was described as “necrotizing enteropathy” in 
autopsy pathology findings of 65 leukemia patients and 7 lymphoma patients.29, 30 
In 1970, Wagner et al27 described the clinical characteristics and radiographic findings in a 
group of pediatric patients with advanced neutropenic enterocolitis identified using 
postmortem findings, and concluded that specific radiographic findings could suggest the 
diagnosis of typhlitis. Katz et al performed an updated postmortem review of 33 pediatric 
patients in 1990, and concluded that improved awareness of the signs and symptom of 
typhlitis, and the setting in which it occurs, may allow for early effective intervention.31 
Sloas et al32 retrospectively identified 24 pediatric patients with neutropenic enterocolitis 
treated at a single institution over 30 years and found that the condition occurred more 
frequently in patients with acute leukemias, and also had the following conclusions: a) 
computed tomography (CT) scans and ultrasonography (US) were more sensitive for 
diagnosis than the plain radiography; b) the increase in the incidence of typhlitis may have 
been due to the wider availability of this imaging technology and to the increase in the 
intensity of the chemotherapeutic regimens; c) most patients responded to aggressive 
medical management, in contrast to prior case reports. 
 Neutropenic enterocolitis has also been reported in adult patients.33, 34 The increase in 
number of reported adult cases was likely due to increased physician awareness and to 
increase in the use of more aggressive chemotherapy. Some authors suggested that surgical 
outcomes may be better in adults compared to pediatric patients.33, 34 Otherwise the clinical 
presentation, radiographic findings and prognosis has been reported as similar in both 
adults and in pediatric cases.   
Besides being primarily associated with acute leukemia, neutropenic enterocolitis has also 
been reported in patients with aplastic anemia, multiple myeloma, myelodysplastic 
syndromes, AIDS, cyclic neutropenia, and neutropenia induced by chemotherapy for solid 
tumors or stem cell transplants.25, 31, 35-39  
A recent single-institution retrospective review of pediatric patients with neutropenic 
enterocolitis who had previously received intensive chemotherapy regimens revealed that 
cytarabine was associated with greater mortality compared to other chemotherapeutic 
agents.40 Cytarabine is considered a prototype drug for the development of chemotherapy-
induced neutropenic colitis as it is the most common agent associated with episodes of 
neutropenic enterocolitis reported in various studies.26, 41  
2.1 Epidemiology 
The true incidence of neutropenic enterocolitis is unknown. Based on autopsy reports, its 
incidence among children with leukemia has been reported as high as 46%.26,31 After a 
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systematic review of the literature that included 21 studies, Gorschluter et al41 calculated the 
pooled incidence rate of neutropenic enterocolitis among adult patients hospitalized for 
hematological malignancies, high-dose chemotherapy for solid tumors, or aplastic anemia to 
be 5.3% (95% confidence interval, 4.7%–5.9%), which was similar to the pooled incidence 
rate of a subgroup of patients with acute leukemias who were treated with 
myelosuppressive chemotherapy (5.6%; 95% confidence interval, 4.6%–6.9%).  
Initial publications of neutropenic enterocolitis cases reported associated mortality rates of 
40–50%.41 A more recent publication reported a mortality rate of 37.5%.42 However, one 
publication reported a mortality rate of 11.7% among pediatric patients.40 Earlier recognition 
of this condition and improvement in its management may have lowered the mortality rates 
associated with neutropenic enterocolitis over the years; however, large series on this 
subject are lacking. 
2.2 Pathogenesis 
The pathogenesis of neutropenic enterocolitis remains unclear but may involve several 
factors including mucosal injury by direct chemotherapy toxicity or leukemic infiltration; 
severe neutropenia; and/or a weakened host defense to intestinal microorganisms.25,36  
Leukemic infiltrates may rarely be implicated, however.31 Neutropenia and infection are 
essential causative factors. Bacteria may invade the bowel wall—a process that neutropenia 
may facilitate—and bacterial endotoxins may infiltrate the bowel, resulting in bacteremia, 
sepsis, necrosis, and hemorrhage. Anatomically, neutropenic enterocolitis almost always 
affects the cecum, possibly because of the cecal dispensability and its low blood supply, but 
can extend to the ascending, transverse, descending, and/or sigmoid colon, as well as the 
terminal ileum.31 Pathology specimens may show mucosal edema, mucosal loss, intramural 
edema, bowel wall thickening (BWT), ulcerations, focal hemorrhage, and/or transmural 
necrosis. Surgical specimens may contain multiple microorganisms, including gram-negative 
rods, gram-positive cocci, anaerobes, enterococci, Candida, and/or cytomegalovirus. 25, 31, 32 
Polymicrobial infection is possible.  
Several cytoxic therapies have been associated with neutropenic enterocolitis. In the earliest 
case reports of neutropenic enterocolitis, the condition was associated with cytotoxic agents 
used to treat leukemias and lymphomas, such as cytarabine, vincristine, doxorubicin, 
methotrexate, cyclophosphamide, etoposide, and prednisone.25,26,31,32 Later studies 
implicated other agents used to treat solid tumors, such as vinorelbine, taxanes, carboplatin, 
cisplatin, gemcitabine and fluorouracil.25,38,43-48 Avigan et al49 reported neutropenic 
enterocolitis in 2 patients who underwent autologous stem cell transplant for solid tumors.  
2.3 Clinical presentation 
The onset of neutropenic enterocolitis symptoms usually occurs 10–14 days after the 
initiation of chemotherapy, when the neutropenia is at its nadir and the patient becomes 
febrile.25 Neutropenic enterocolitis should be suspected in any patient with profound 
neutropenia (absolute neutrophil count <500 neutrophils/µl), fever, and right lower 
quadrant abdominal pain. Nausea, vomiting, abdominal distention, and watery or bloody 
diarrhea may also be present.26,31,50,51 An acute surgical abdomen with peritoneal signs and 
septic shock may suggest bowel perforation.  
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2.4 Diagnosis 
Currently, there is no consensus on standardized diagnostic criteria for neutropenic 
enterocolitis. A recently published diagnostic criteria for neutropenic enterocolitis was 
proposed by Gorschluter et al41:  
 Presence of fever (axillary temperature >38.0°C or rectal temperature >38.5°C)  
 Abdominal pain (self reported as grade 3 or more using a visual analogous pain score 
ranging from 1 to 10) 
 US or CT demonstration of BWT of >4 mm (transverse scan) over >30 mm (longitudinal 
scan) in any segment  
Pathologic examination of the cecum or affected area would be considered the gold standard 
but is not practical as colonoscopy and colonic biopsy are generally contraindicated because 
of the increased risk of bowel perforation, intraabdominal infection, and (especially in 
thrombocytopenic patients) bleeding.  
Imaging studies are recommended to support the clinical diagnosis. Abdominal CT  scan 
(without oral contrast) tends to be preferred over plain abdominal films because CT scan 
seems to have a lower false-negative rate of diagnosis and is better able to differentiate 
neutropenic enterocolitis from acute appendicitis or appendiceal abscess.32 However, CT 
scan cannot be performed easily in severely ill patients. Therefore, ultrasonography may 
complement CT or replace it as the diagnostic modality of choice in select patients. In one 
prospective study, US revealed BWT of >4 mm in all 4 patients with neutropenic colitis and 
in 1 patient with mucositis, leading the authors to conclude that BWT of >4 mm is a good 
discriminator to make a clinical diagnosis of neutropenic enterocolitis.52  
Radiological findings suggestive of neutropenic enterocolitis include BWT, a dilated and 
fluid-filled cecum, diffuse cecal wall thickening, an inflammatory mass in the right-lower 
quadrant, pericecal fluid, and inflammatory changes in the pericecal soft tissues.25,32 Plain 
films may be normal or show nonspecific findings and occasionally reveal a fluid-filled, 
distended cecum with dilated adjacent small bowel loops, thumb printing, or localized 
pneumatosis intestinalis.26 Barium enemas are usually contraindicated, as they could lead to 
bowel perforation.  
Using an US-measured BWT of >5 mm as the cutoff point for diagnosis, Cartoni et al53 
demonstrated that patients with a positive US had a significantly longer mean duration of 
symptoms (7.9 days vs. 3.8 days) and a higher mortality rate (29% vs. 0%) than patients with 
a negative US. Furthermore, among patients with a positive US, the mortality rate among 
patients with a BWT of >10 mm (60%) was significantly higher than the mortality rate 
among patients with a BWT of ≤10 mm (4.2%).  
However, BWT may not be specific for neutropenic enterocolitis alone. For example, a 
retrospective review of abdominal CT findings in 76 neutropenic patients revealed that BWT 
was most common in patients with C. difficile colitis, whereas the primary finding in patients 
with neutropenic enterocolitis and bowel ischemia was pneumatosis.54 The specific use of 
BWT to diagnose neutropenic enterocolitis is thus a matter of debate, and a prospective 
validation study is needed.  
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2.5 Treatment 
There is no standardized treatment guideline for neutropenic enterocolitis because of a 
lack of prospective randomized trials. Treatment decisions for patients with neutropenic 
enterocolitis are therefore based on descriptive or retrospective studies and clinical 
experts’ opinions. A conservative treatment approach consisting of a combination of 
blood products support, broad-spectrum antibiotics, and bowel rest achieved by 
intravenous fluids and total parenteral nutrition has been recommended for patients who 
present without complications such as peritonitis, perforation, or massive bleeding.55,56 
Antibiotic coverage for C. difficile infection should be added if this infection has not been 
ruled out.32 Antifungal treatment should also be considered, as per the guidelines for the 
management of neutropenic fever. Granulocyte colony-stimulating factor (G-CSF) may 
also be used to accelerate recovery from neutropenia.25,26,47,57 Although case report series 
have reported the benefit of granulocyte transfusions,58 such therapy is not recommended 
by consensus. Anticholinergic, anti- diarrheal, and opioid agents should be avoided 
because they may worsen ileus. 
In 1979, Varki et al59 reported a case of severe neutropenic enterocolitis in which early 
clinical recognition and surgical intervention resulted in survival advantage. Surgical 
intervention is recommended for patients with refractory gastrointestinal bleeding (after 
correcting cytopenias or coagulopathy), peritonitis, bowel perforation and patients who 
continue to deteriorate despite medical management.25,26 The standard surgical approach is 
a 2-stage right hemicolectomy,25 as neutropenia may impede primary bowel anastomoses.60  
Because the likelihood of developing a second episode of neutropenic enterocolitis during a 
subsequent cycle of chemotherapy is notable, patients should be allowed to completely 
recover from an episode of neutropenic enterocolitis before subsequent chemotherapy is 
administered.25  
3. Taxane-induced (ischemic) Colitis 
Taxane-induced colitis is a recognized and a distinguished entity of the classically recognized 
neutropenic colitis or typhlitis. As its name suggest, patients with neutropenic colitis are 
neutropenic and commonly febrile, occurring at about 2 weeks of the administration of 
chemotherapy; on the otherhand, taxane- induced colitis occurs at a shorter interval, and is not 
necessarily associated with neutropenia or fever. Lower abdominal pain with or without 
diarrhea or blood per rectum should alert the physician to its occurrence.   
In 2000, our group reported 6 patients with docetaxel-associated ischemic colitis.5 Because of 
the early onset of symptoms, these patients did not fit the classic picture of neutropenic 
enterocolitis; besides, not all these patients were neutropenic or febrile, the cardinal features 
of neutropenic enterocolitis. Three patients had received docetaxel in combination with 
vinorelbine in a phase I trial. The other 3 patients were identified during a scheduled review 
of toxic effects in subjects enrolled in clinical trials receiving docetaxel: one of the patients 
received docetaxel as single agent, another patient received it in combination with 
pamindronate and the last one received it in combination with cyclophosphamide. Other 
studies have also noted as well the association of taxane-induced colitis with docetaxel with 
or without its combination with vinorelbine, another antitubulin agent.6 There have been 
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several case reports of patients who developed ischemic colitis and had a normal or high 
white blood cell counts after receiving paclitaxel7, 8 or nab-paclitaxel (Dr. Nuhad Ibrahim, 
personal communication).  
Of the 1,350 breast cancer patients who received taxane-based chemotherapy at MD 
Anderson Cancer Center between 1997 and 1999, 14 were diagnosed with colitis.9 Of the 520 
patients who received docetaxel, 10 patients (1.9%) developed colitis, and of the 830 patients 
who received paclitaxel, 4 patients (0.5%) developed colitis. The clinical data of these 14 
patients were used to describe the characteristics of taxane-induced colitis. Colitis recurred 
in 2 patients who were re-challenged with the same taxane and at the same dose-schedule. 
CT scan findings typically showed diffuse or localized thickening of the colonic wall and 
revealed pneumoperitoneum in 1 patient. Colonoscopy confirmed ischemic colitis in 2 
patients. Blood cultures were positive for coagulase-negative Staphylococcus in 3 (20%) of the 
colitis events, in addition to Stenotrophomonas maltophilia in 1 of these events. All patients 
had negative C. defficile titers. All patients who developed colitis received supportive care 
with intravenous fluids and broad-spectrum antibiotics. One patient died of septic shock. 
Two patients underwent hemicolectomy, the pathology of which revealed bowel perforation 
secondary to transmural necrosis.  
3.1 Pathogenesis 
The mechanism of taxane-induced colitis is unknown. Bowel necrosis or perforation may be 
a direct effect of the drug’s rendering microtubule bundles nonfunctional, resulting in 
transient mitotic arrest. Paclitaxel is also known to have antiangiogenic activity and can 
induce apoptosis, which could account for the necrosis observed in biopsy samples of 
affected bowel; however, this has not been validated.9, 10  
3.2 Clinical presentation and diagnosis 
The diagnosis of taxane-induced colitis is based on the presence of acute, usually supra pubic 
abdominal pain with or without neutropenia, fever, diarrhea, or hematochezia. While blood 
cultures may or not be positive, C. difficile titers are always negative. Taxane-induced colitis 
tends to occur early in the course of the chemotherapy, with a reported median onset of 6 days 
after the start of a taxane administered every 3 weeks. Colitis onset occurs within 72 hours 
when the taxane is given weekly, however (Not published data, DR Nuhad Ibrahim).  
The radiographic findings of taxane-induced colitis are not specific. CT scan of abdomen 
and pelvis may reveal involvement of any segment of the bowel or pan colitis as well as 
BWT, peritoneal stranding, and/or ascites.10 The cecum may not be involved, as is almost 
always the case in patients with neutropenic enterocolitis. Histological analysis of a biopsied 
sample typically reveals ischemic features. Colonoscopy is not recommended because of the 
risk of bowel perforation. 
3.3 Treatment 
Aggressive supportive care with intravenous fluids, broad-spectrum antibiotics, and close 
surgical monitoring until the symptoms have resolved is recommended. Because taxane-
www.intechopen.com
 
Chemotherapy–Induced Colitis 121 
induced colitis seems to be dose-related, the taxane dose should be reduced or discontinued 
to prevent a recurrence.  
4. Anti-cytotoxic T-lymphocyte antigen-4 antibody–induced enterocolitis  
One novel method of treating cancer is using monoclonal antibodies to target molecules that 
enhance antitumor immunity. One such molecule, cytotoxic T-lymphocyte antigen-4 (CTLA-
4) is a T-cell receptor whose primary role is to down regulate T-cell activation, which results 
in immune-tolerance to self-antigens and prevents damage to normal host tissue.61 
Preclinical data have shown that CTLA-4 antibodies induce antitumor activity. Anti-CTLA-4 
therapy indirectly targets tumor cells by activating the immune system against the tumor.62 
Two human monoclonal antibodies against CTLA-4 have been developed: ipilimumab, 
which was recently approved by the U.S. Food and Drug Administration for the treatment 
of metastatic melanoma, and tremelimumab.63  
4.1 Pathogenesis 
Clinical trials of anti-CTLA-4 therapy have revealed a relationship between tumor response 
and immune-related adverse events, suggesting that the anti-CTLA-4 antibody’s mechanism 
of antitumor action may also affect the normal tissue and explain why this therapy is 
associated with a spectrum of side effects, including enterocolitis.12,13 Several mechanisms 
by which the CTLA-4 blockade exerts its antitumor activity have been proposed: anti-CTLA-
4 agents may block CD4+ and CD25+ regulatory T cells, which normally suppress the 
function and proliferation of tumor-specific CD4+ and CD8+ effector T cells and natural 
killer cells; or the CTLA-4 blockade may enable the proliferation and enhance the function of 
effector CD4+ and CD8+ cells, thereby inducing antibody responses; or anti-CTLA-4 
antibodies may also cause direct cytotoxicity by directly binding to tumor cells that 
constitutively express CTLA-4.14, 62  
The reported safety profiles of CTLA-4 blockade in melanoma patients and in patients with 
other cancers such as lung, prostate, and renal cancer are similar, which suggests the 
therapy has class-specific toxicity. The immune-related adverse events in patients receiving 
anti-CTLA-4 therapy are thought to be the result of nonspecific or cross-reactive tissue 
damage caused by activated T cells.13  
Others have suggested that intestinal micro flora and bacterial antigens may be contributing 
factors to the enterocolitis seen in patients with graft-versus-host disease .64 This type of 
enterocolitis may have a similar pathogenesis to the enterocolitis associated with anti-CTLA-
4 antibodies. Future clinical research should evaluate the role of prophylactic antibiotics in 
this entity. 
Studies have found an association between enterocolitis and objective tumor regression in 
melanoma patients and renal cell carcinoma patients, suggesting that enterocolitis could be 
a surrogate marker of drug efficacy.11 
4.2 Clinical presentation 
The most common grade 3 or 4 adverse events reported in clinical trials of anti-CTLA-4 
therapy are enterocolitis, dermatitis, hepatitis, hypophysitis, and uveitis. The most frequent 
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gastrointestinal adverse event in patients with anti-CTLA-4 antibody–induced immune-
breakthrough enterocolitis is diarrhea. 
Beck et al11 found that of 198 patients with metastatic melanoma or renal cell carcinoma that 
were treated with ipilimumab, 41 patients (21%) had been diagnosed with enterocolitis. The 
hallmark symptom was diarrhea, which occurred in 40 patients (98%) and whose occurrence 
ranged from 3 soft stools per day to 20 watery stools daily. Other presenting symptoms 
included abdominal pain (20%), nausea/vomiting (15%), fever (12%), anal pain (10%), rectal 
bleeding (2%), and constipation (2%). The median time from the last dose of ipilimumab to 
the onset of symptoms was 11 days (range, 0–59 days), and there was no predictable pattern 
of symptomology.  
Other studies have reported that diarrhea occurs in up to 44% of patients treated with 
ipilimumab, with grade 2 or worse diarrhea occurring in about 35% of patients and grade 3 
or 4 diarrhea occurring in around 18% of patients.14 One study reported a median time to 
diarrhea onset of 14 days (range, 5–36 days).13 Generally, patients have watery or loose 
diarrhea that occurs 4–8 times a day without blood, fever, nausea, vomiting, or weight loss. 
Some patients may have abdominal pain.  
4.3 Diagnosis 
This clinical entity should be suspected in patients receiving a CTLA-4 antibody who 
develop diarrhea, and in whom other causes of diarrhea have been ruled out. Infectious 
diarrhea, such as that caused by parasites or C. difficile, should be excluded. Beck et al11 
considered patients to have enterocolitis if they had biopsy findings showing enterocolitis or 
had sudden-onset diarrhea with no alternative etiology, which lessened or resolved with 
steroids. Macroscopic findings include erythema, edema, friability, and erosions.13 
Histopathological analysis typically reveals neutrophilic inflammation (46% of patients), 
lymphocytic inflammation (15% of patients), or a combination of neutrophilic and 
lymphocytic inflammation (38% of patients).11  
4.4 Treatment 
The management of anti-CTLA-4 antibody–induced immune-breakthrough enterocolitis is 
based on the severity of the diarrhea. Guidelines and treatment algorithms have been 
published.12,14 Patients who develop grade 1 diarrhea should receive symptomatic treatment 
and supportive care. In patients with grade 2 diarrhea, stool studies and colonoscopy can be 
used to determine whether enterocolitis is present; once the condition is confirmed, 
treatment is initiated with oral budesonide or prednisone tapering over a minimum of 4 
weeks. Patients with grade 3 or 4 diarrhea should be given high-dose steroids such as 
intravenous methylprednisolone (2 mg/kg) once or twice a day with a minimum taper of 4 
weeks. Patients whose enterocolitis is steroid-refractory should be given infliximab.65 
Patients on long-term immunosuppressive therapy should be given prophylactic 
antimicrobials. Patients receiving anti-CTLA-4 antibody should be educated about immune-
related adverse events, which can occur at any time during therapy and require timely 
treatment.13 
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 Neutropenic 
Enterocolitis 
Ischemic Colitis Anti-CTLA4 Antibody 
Enterocolitis 
Incidence, % 5.3 a 1.03b 21,c 44d 
Chemotherapy Various Taxanes Ipilimumab 
Tremelimumab 
Symptoms Neutropenia, fever, and 
RLQ abdominal pain  
Lower (suprapubic) 
abdominal pain with or 
without diarrhea or 
hematochezia and the 
absence of C. difficile. 
Fever and neutropenia 
are not sufficient but not 
necessary features.  
Diarrhea (watery or 
loose, without blood) 
occurring 4–8 times a 
day without fever, 
nausea, vomiting, or 
weight loss. Some 
patients have abdominal 
pain. 
Median time to 
symptom 
onset, days 
(range) 
12 (10-14)e 6 (3–8) 11 (0–59) 
Diagnosis Clinical presentation 
and radiologic finding. 
Clinical presentation 
and radiologic findings. 
Ischemic colitis is the 
hallmark pathologic 
finding. 
Clinical presentation. 
Histopathology 
evaluation may reveal 
neutrophilic and/or 
lymphocytic 
inflammation. 
Radiologic 
findings 
Cecal involvement is 
necessary and/or 
sufficient; additional 
colonic segments, pan-
colonic, or distal ileum 
may be involved. US or 
CT may reveal bowel 
wall thickening > 4 mm 
(transverse scan) over 
more than 30 mm 
(longitudinal scan) in 
any. 
Not specific. Any 
segment of the bowel 
may be involved; 
disease may be pan-
colonic. Cecal 
involvement may be 
sufficient but not 
necessary. CT scan may 
reveal bowel wall 
thickening, peritoneal 
stranding, or ascites 
Not specific 
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Treatment Conservative 
management includes 
bowel rest, IV fluids, 
antibiotics, and G-CSF. 
Surgical intervention is 
reserved for patients 
with peritonitis, bowel 
perforation, or massive 
bleeding.  
Supportive care with IV 
fluids, antibiotics, and 
close surgical 
monitoring. 
Symptomatic treatment, 
steroids, or infliximab, 
depending on the 
severity of the symptom 
CTLA 4, cytotoxic T-lymphocyte antigen 4; RLQ, right lower quadrant; CT, computed tomography; US, 
ultrasonography; IV, intravenous; G-CSF, granulocyte-colony stimulating factor.  
a Gorschluter M, Mey U, Strehl J, et al, Eur J Haematol 2005 
b Li Z, Ibrahim NK, Wathen JK, et al, Cancer 2004 
c Beck KE, Blansfield JA, Tran KQ, et al, J Clin Oncol 2006 
d Kaehler KC, Piel S, Livingstone E, et al, Semin Oncol 2010 
e Davila ML, Curr Opin Gastroenterol 2006 
Table 1. Comparison of characteristics of three types of chemotherapy-induced colitis 
5. Conclusion 
Chemotherapy-induced colitis is a significant complication of multiple chemotherapeutic 
agents. Its occurrence adds not only to the morbidity of the patient, but also may impact the 
treatment choices of the patient’s cancer management. Early recognition may help the 
patient avoid grave consequences including death related to its severity. It is therefore 
essential that it is recognized in its different forms and the various drugs it may be 
associated with. It remains an uncommon event, however, but early appraisal of the 
presenting symptom complex in the context of chemotherapy administration is prudent.  
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